keyword
https://read.qxmd.com/read/36976738/-association-of-the-level-of-serum-prolactin-with-polymorphic-variants-of-the-grin2a-gpm3-and-gpm7-genes-in-patients-with-schizophrenia-taking-conventional-and-atypical-antipsychotics
#21
JOURNAL ARTICLE
V V Tiguntsev, V I Gerasimova, E G Kornetova, O Yu Fedorenko, A N Kornetov, A A Goncharova, E G Poltavskaya, A S Boyko
The dopamine, serotonin and glutamate systems are jointly involved in the pathogenesis and pharmacotherapy of schizophrenia. We formulated a hypothesis that polymorphic variants of the GRIN2A, GRM3, and GRM7 genes may be associated with the development of hyperprolactinemia in patients with schizophrenia taking conventional and atypical antipsychotics as basic treatment. 432 Caucasian patients diagnosed with schizophrenia were examined. DNA was isolated from peripheral blood leukocytes using the standard phenol-chloroform method...
2023: Molekuliarnaia Biologiia
https://read.qxmd.com/read/36768378/neurotoxic-neuroprotective-effects-of-clozapine-and-the-positive-allosteric-modulator-of-mglur2-jnj-46356479-in-human-neuroblastoma-cell-cultures
#22
JOURNAL ARTICLE
Patricia Gassó, Albert Martínez-Pinteño, Natalia Rodríguez, Santiago Madero, Marta Gómez, Alex G Segura, Clemente García-Rizo, Constanza Morén, Sergi Mas, Eduard Parellada
Current antipsychotics (APs) effectively control positive psychotic symptoms, mainly by blocking dopamine (DA) D2 receptors, but have little effect on negative and cognitive symptoms. Increased glutamate (GLU) release would trigger neurotoxicity, leading to apoptosis and synaptic pruning, which is involved in the pathophysiology of schizophrenia. New pharmacological strategies are being developed such as positive allosteric modulators (PAMs) of the metabotropic GLU receptor 2 (mGluR2) that inhibit the presynaptic release of GLU...
January 20, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/36640734/the-substantia-nigra-in-the-pathology-of-schizophrenia-a-review-on-post-mortem-and-molecular-imaging-findings
#23
REVIEW
Carmen F M van Hooijdonk, Marieke van der Pluijm, Iris Bosch, Therese A M J van Amelsvoort, Jan Booij, Lieuwe de Haan, Jean-Paul Selten, Elsmarieke van de Giessen
Dysregulation of striatal dopamine is considered to be an important driver of pathophysiological processes in schizophrenia. Despite being one of the main origins of dopaminergic input to the striatum, the (dys)functioning of the substantia nigra (SN) has been relatively understudied in schizophrenia. Hence, this paper aims to review different molecular aspects of nigral functioning in patients with schizophrenia compared to healthy controls by integrating post-mortem and molecular imaging studies. We found evidence for hyperdopaminergic functioning in the SN of patients with schizophrenia (i...
January 12, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/36634450/music-rhythm-perception-and-production-relate-to-treatment-response-in-schizophrenia
#24
JOURNAL ARTICLE
Shiori Honda, Karin Matsushita, Yoshihiro Noda, Ryosuke Tarumi, Natsumi Nomiyama, Sakiko Tsugawa, Shinichiro Nakajima, Masaru Mimura, Shinya Fujii
Accumulating evidence indicates that pathophysiology of schizophrenia involves abnormalities in the dopamine and glutamatergic neuronal systems. Antipsychotic medications are currently used to normalize dopaminergic function for schizophrenia. However, approximately 30 % of the patients have no response to antipsychotic medications, which is classified as treatment-resistant schizophrenia (TRS). Furthermore, dopamine and glutamate levels in the neural basis have been reported to differ between TRS and non-TRS...
January 10, 2023: Schizophrenia Research
https://read.qxmd.com/read/36551939/antipsychotics-induced-changes-in-synaptic-architecture-and-functional-connectivity-translational-implications-for-treatment-response-and-resistance
#25
REVIEW
Andrea de Bartolomeis, Giuseppe De Simone, Mariateresa Ciccarelli, Alessia Castiello, Benedetta Mazza, Licia Vellucci, Annarita Barone
Schizophrenia is a severe mental illness characterized by alterations in processes that regulate both synaptic plasticity and functional connectivity between brain regions. Antipsychotics are the cornerstone of schizophrenia pharmacological treatment and, beyond occupying dopamine D2 receptors, can affect multiple molecular targets, pre- and postsynaptic sites, as well as intracellular effectors. Multiple lines of evidence point to the involvement of antipsychotics in sculpting synaptic architecture and remodeling the neuronal functional unit...
December 8, 2022: Biomedicines
https://read.qxmd.com/read/36551925/pharmacogenetics-and-schizophrenia-can-genomics-improve-the-treatment-with-second-generation-antipsychotics
#26
REVIEW
Olga Płaza, Piotr Gałecki, Agata Orzechowska, Małgorzata Gałecka, Justyna Sobolewska-Nowak, Agata Szulc
Schizophrenia (SCZ) is a complex psychiatric disorder of multifactorial origin, in which both genetic and environmental factors have an impact on its onset, course, and outcome. Large variability in response and tolerability of medication among individuals makes it difficult to predict the efficacy of a chosen therapeutic method and create universal and precise guidelines for treatment. Pharmacogenetic research allows for the identification of genetic polymorphisms associated with response to a chosen antipsychotic, thus allowing for a more effective and personal approach to treatment...
December 7, 2022: Biomedicines
https://read.qxmd.com/read/36504683/inhibition-of-glycogen-synthase-kinase-3-by-lithium-a-mechanism-in-search-of-specificity
#27
REVIEW
Dipashree Chatterjee, Jean Martin Beaulieu
Inhibition of Glycogen synthase kinase 3 (GSK3) is a popular explanation for the effects of lithium ions on mood regulation in bipolar disorder and other mental illnesses, including major depression, cyclothymia, and schizophrenia. Contribution of GSK3 is supported by evidence obtained from animal and patient derived model systems. However, the two GSK3 enzymes, GSK3α and GSK3β, have more than 100 validated substrates. They are thus central hubs for major biological functions, such as dopamine-glutamate neurotransmission, synaptic plasticity (Hebbian and homeostatic), inflammation, circadian regulation, protein synthesis, metabolism, inflammation, and mitochondrial functions...
2022: Frontiers in Molecular Neuroscience
https://read.qxmd.com/read/36463316/glutamatergic-dysfunction-in-schizophrenia
#28
REVIEW
Andreas O Kruse, Juan R Bustillo
The NMDA-R hypofunction model of schizophrenia started with the clinical observation of the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or ketamine. Healthy volunteers exposed to acute low doses of ketamine experienced mild psychosis but also negative and cognitive type symptoms reminiscent of the full clinical picture of schizophrenia. In rodents, acute systemic ketamine resulted in a paradoxical increase in extracellular frontal glutamate as well as of dopamine. Similar increase in prefrontal glutamate was documented with acute ketamine in healthy volunteers with 1 H-MRS...
December 3, 2022: Translational Psychiatry
https://read.qxmd.com/read/36350433/reversal-and-preventive-pleiotropic-mechanisms-involved-in-the-antipsychotic-like-effect-of-taurine-an-essential-%C3%AE-amino-acid-in-ketamine-induced-experimental-schizophrenia-in-mice
#29
JOURNAL ARTICLE
Benneth Ben-Azu, Christian I Uruaka, Abayomi M Ajayi, Thiophilus Aghogho Jarikre, Kingsley E Nwangwa, Kingsley C Chilaka, Bienose S Chijioke, Marymagdalene G Omonyeme, Chineye B Ozege, Emmanuella C Ofili, Ebidenara B Warekoromor, Nwanneka L Edigbue, Ufoma V Esiekpe, Dabrechi E Akaenyi, Gladys O Agu
Schizophrenia is a life disabling, multisystem neuropsychiatric disease mostly derived from complex epigenetic-mediated neurobiological changes causing behavioural deficits. Neurochemical disorganizations, neurotrophic and neuroimmune alterations are some of the challenging neuropathologies proving unabated during psychopharmacology of schizophrenia, further bedeviled by drug-induced metabolic derangements including alteration of amino acids. In first-episode schizophrenia patients, taurine, an essential β-amino acid represses psychotic-symptoms...
November 9, 2022: Neurochemical Research
https://read.qxmd.com/read/36268829/altered-patterns-of-brain-glucose-metabolism-involve-more-extensive-and-discrete-cortical-areas-in-treatment-resistant-schizophrenia-patients-compared-to-responder-patients-and-controls-results-from-a-head-to-head-2-18f-fdg-pet-study
#30
JOURNAL ARTICLE
Felice Iasevoli, Luigi D'Ambrosio, Mariateresa Ciccarelli, Annarita Barone, Valeria Gaudieri, Sirio Cocozza, Giuseppe Pontillo, Arturo Brunetti, Alberto Cuocolo, Andrea de Bartolomeis, Sabina Pappatà
BACKGROUND AND HYPOTHESIS: Treatment resistant schizophrenia (TRS) affects almost 30% of patients with schizophrenia and has been considered a different phenotype of the disease. In vivo characterization of brain metabolic patterns associated with treatment response could contribute to elucidate the neurobiological underpinnings of TRS. Here, we used 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) to provide the first head-to-head comparative analysis of cerebral glucose metabolism in TRS patients compared to schizophrenia responder patients (nTRS), and controls...
October 21, 2022: Schizophrenia Bulletin
https://read.qxmd.com/read/36232936/haloperidol-induced-immediate-early-genes-in-striatopallidal-neurons-requires-the-converging-action-of-camp-pka-darpp-32-and-mtor-pathways
#31
JOURNAL ARTICLE
Oriane Onimus, Emmanuel Valjent, Gilberto Fisone, Giuseppe Gangarossa
Antipsychotics share the common pharmacological feature of antagonizing the dopamine 2 receptor (D2R), which is abundant in the striatum and involved in both the therapeutic and side effects of this drug's class. The pharmacological blockade of striatal D2R, by disinhibiting the D2R-containing medium-sized spiny neurons (MSNs), leads to a plethora of molecular, cellular and behavioral adaptations, which are central in the action of antipsychotics. Here, we focused on the cell type-specific (D2R-MSNs) regulation of some striatal immediate early genes (IEGs), such as cFos, Arc and Zif268...
October 1, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36206872/mechanisms-underpinning-carpolobia-lutea-g-don-ethanol-extract-s-neurorestorative-and-antipsychotic-like-activities-in-an-nmda-receptor-antagonist-model-of-schizophrenia
#32
JOURNAL ARTICLE
Noah A Omeiza, Adewale Bakre, Benneth Ben-Azu, Abimbola A Sowunmi, Halimat A Abdulrahim, Joseph Chimezie, Sodiq O Lawal, Olusegun G Adebayo, Abdullateef I Alagbonsi, Olugbenga Akinola, Amos O Abolaji, Adegbuyi O Aderibigbe
ETHNOPHARMACOLOGICAL RELEVANCE: Persistent ketamine insults to the central nervous system block NMDA receptors and disrupt putative neurotransmission, oxido-nitrosative, and inflammatory pathways, resulting in schizophrenia-like symptoms in animals. Previously, the ethnomedicinal benefits of Carpolobia lutea against insomnia, migraine headache, and insanity has been documented, but the mechanisms of action remain incomplete. AIM OF THE STUDY: Presently, we explored the neuro-therapeutic role of Carpolobia lutea ethanol extract (C...
October 4, 2022: Journal of Ethnopharmacology
https://read.qxmd.com/read/36187336/insights-into-the-promising-prospect-of-g-protein-and-gpcr-mediated-signaling-in-neuropathophysiology-and-its-therapeutic-regulation
#33
REVIEW
Md Mominur Rahman, Md Rezaul Islam, Sadia Afsana Mim, Nasrin Sultana, Dinesh Kumar Chellappan, Kamal Dua, Mohammad Amjad Kamal, Rohit Sharma, Talha Bin Emran
G protein-coupled receptors (GPCRs) are intricately involved in the conversion of extracellular feedback to intracellular responses. These specialized receptors possess a crucial role in neurological and psychiatric disorders. Most nonsensory GPCRs are active in almost 90% of complex brain functions. At the time of receptor phosphorylation, a GPCR pathway is essentially activated through a G protein signaling mechanism via a G protein-coupled receptor kinase (GRK). Dopamine, an important neurotransmitter, is primarily involved in the pathophysiology of several CNS disorders; for instance, bipolar disorder, schizophrenia, Parkinson's disease, and ADHD...
2022: Oxidative Medicine and Cellular Longevity
https://read.qxmd.com/read/36160447/a-mechanistic-overview-of-approaches-for-the-treatment-of-psychostimulant-dependence
#34
REVIEW
Kathrine Louise Jensen, Søren Brøgger Jensen, Kenneth Lindegaard Madsen
Psychostimulant use disorder is a major health issue around the world with enormous individual, family-related and societal consequences, yet there are no effective pharmacological treatments available. In this review, a target-based overview of pharmacological treatments toward psychostimulant addiction will be presented. We will go through therapeutic approaches targeting different aspects of psychostimulant addiction with focus on three major areas; 1) drugs targeting signalling, and metabolism of the dopamine system, 2) drugs targeting either AMPA receptors or metabotropic glutamate receptors of the glutamate system and 3) drugs targeting the severe side-effects of quitting long-term psychostimulant use...
2022: Frontiers in Pharmacology
https://read.qxmd.com/read/35963926/linking-inflammation-aberrant-glutamate-dopamine-interaction-and-post-synaptic-changes-translational-relevance-for-schizophrenia-and-antipsychotic-treatment-a-systematic-review
#35
REVIEW
Andrea de Bartolomeis, Annarita Barone, Licia Vellucci, Benedetta Mazza, Mark C Austin, Felice Iasevoli, Mariateresa Ciccarelli
Evidence from clinical, preclinical, and post-mortem studies supports the inflammatory/immune hypothesis of schizophrenia pathogenesis. Less evident is the link between the inflammatory background and two well-recognized functional and structural findings of schizophrenia pathophysiology: the dopamine-glutamate aberrant interaction and the alteration of dendritic spines architecture, both believed to be the "quantal" elements of cortical-subcortical dysfunctional network. In this systematic review, we tried to capture the major findings linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes under a direct and inverse translational perspective, a paramount picture that at present is lacking...
October 2022: Molecular Neurobiology
https://read.qxmd.com/read/35955750/beyond-nmda-receptors-homeostasis-at-the-glutamate-tripartite-synapse-and-its-contributions-to-cognitive-dysfunction-in-schizophrenia
#36
REVIEW
Hagar Bauminger, Inna Gaisler-Salomon
Cognitive deficits are core symptoms of schizophrenia but remain poorly addressed by dopamine-based antipsychotic medications. Glutamate abnormalities are implicated in schizophrenia-related cognitive deficits. While the role of the NMDA receptor has been extensively studied, less attention was given to other components that control glutamate homeostasis. Glutamate dynamics at the tripartite synapse include presynaptic and postsynaptic components and are tightly regulated by neuron-astrocyte crosstalk. Here, we delineate the role of glutamate homeostasis at the tripartite synapse in schizophrenia-related cognitive dysfunction...
August 3, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35883465/rational-and-translational-implications-of-d-amino-acids-for-treatment-resistant-schizophrenia-from-neurobiology-to-the-clinics
#37
REVIEW
Andrea de Bartolomeis, Licia Vellucci, Mark C Austin, Giuseppe De Simone, Annarita Barone
Schizophrenia has been conceptualized as a neurodevelopmental disorder with synaptic alterations and aberrant cortical-subcortical connections. Antipsychotics are the mainstay of schizophrenia treatment and nearly all share the common feature of dopamine D2 receptor occupancy, whereas glutamatergic abnormalities are not targeted by the presently available therapies. D-amino acids, acting as N-methyl-D-aspartate receptor (NMDAR) modulators, have emerged in the last few years as a potential augmentation strategy in those cases of schizophrenia that do not respond well to antipsychotics, a condition defined as treatment-resistant schizophrenia (TRS), affecting almost 30-40% of patients, and characterized by serious cognitive deficits and functional impairment...
June 29, 2022: Biomolecules
https://read.qxmd.com/read/35878581/lumateperone-mediated-effects-on-prefrontal-glutamatergic-receptor-mediated-neurotransmission-a-dopamine-d-1-receptor-dependent-mechanism
#38
JOURNAL ARTICLE
J Titulaer, O Radhe, K Danielsson, S Dutheil, M M Marcus, K Jardemark, T H Svensson, G L Snyder, M Ericson, R E Davis, Å Konradsson-Geuken
Lumateperone is a novel drug approved for the treatment of schizophrenia in adults and depressive episodes associated with bipolar depression in adults, as monotherapy and as adjunctive therapy with lithium or valproate treatment in the United States. Lumateperone simultaneously modulates key neurotransmitters, such as serotonin, dopamine, and glutamate, implicated in serious mental illness. In patients with schizophrenia, lumateperone was shown to improve positive symptoms along with negative and depressive symptoms, while also enhancing prosocial behavior...
July 22, 2022: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/35802228/lumateperone-for-the-treatment-of-adults-with-schizophrenia-a-systematic-review
#39
REVIEW
Muhammad Youshay Jawad, Yazen Alnefeesi, Felicia Ceban, Leanna M W Lui, Saja Jaberi, Joshua D Di Vincenzo, Leila Amirbeik, David C J Chen-Li, Kayla Teopiz, Lee Phan, Bing Cao, Roger Ho, Joshua D Rosenblat, Roger S McIntyre
PURPOSE OF REVIEW: Lumateperone (LUM) is the U.S. Food and Drug Administration approved atypical antipsychotic agent for adults with schizophrenia (SCZ) and bipolar depression (for both bipolar I and bipolar II disorder as as monotherapy or as adjunctive treatment to lithium or valproate). LUM simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. The foregoing pleiotropic mechanism of action is predictive of therapeutic benefits across multiple domains of psychopathology in SCZ (i...
August 2022: Current Psychiatry Reports
https://read.qxmd.com/read/35669271/add-on-memantine-to-dopamine-antagonism-to-improve-negative-symptoms-at-first-psychosis-the-amend-trial-protocol
#40
JOURNAL ARTICLE
Katharina O Sandström, Olga B Baltzersen, Anouk Marsman, Cecilie K Lemvigh, Vincent O Boer, Kirsten B Bojesen, Mette Ø Nielsen, Henrik Lundell, Daban K Sulaiman, Mikkel E Sørensen, Birgitte Fagerlund, Adrienne C Lahti, Warda T Syeda, Christos Pantelis, Esben T Petersen, Birte Y Glenthøj, Hartwig R Siebner, Bjørn H Ebdrup
Background: Antipsychotic drugs are primarily efficacious in treating positive symptoms by blocking the dopamine D2 receptor, but they fail to substantially improve negative symptoms and cognitive deficits. The limited efficacy may be attributed to the fact that the pathophysiology of psychosis involves multiple neurotransmitter systems. In patients with chronic schizophrenia, memantine, a non-competitive glutamatergic NMDA receptor antagonist, shows promise for ameliorating negative symptoms and improving cognition...
2022: Frontiers in Psychiatry
keyword
keyword
82525
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.